(Q40563800)

English

The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.

scientific article published on July 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Andrea Bolognesi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Pier Luigi Zinzani

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Tazzari PL

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Farini V

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Lubelli C

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Ricci F

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Stirpe F

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

1 July 2004

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1215-1222

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403378

0 references

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Radioimmunotherapy of non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Immunotoxins for targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Ribosome-inactivating proteins from plants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Ribosome-inactivating proteins from plants: more than RNA N-glycosidases?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Polynucleotide:adenosine glycosidase activity of ribosome-inactivating proteins: effect on DNA, RNA and poly(A).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Ribosome-inactivating and adenine polynucleotide glycosylase activities in Mirabilis jalapa L. tissues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Immunotoxins: an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Nucleoside analogues in the treatment of haematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Improving the efficacy of antibody-based cancer therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Are immunoconjugates useful for therapy with autoimmune diseases?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Cell surface antigen and molecular targeting in the treatment of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

21 January 2018

Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

7 January 2021

based on heuristic

inferred from DOI database lookup

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

7 January 2021

based on heuristic

inferred from DOI database lookup

Complement activation plays a key role in the side-effects of rituximab treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

7 January 2021

based on heuristic

inferred from DOI database lookup

An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403378

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403378

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Dimensions Publication ID

0 references

release_6n3nphee4rh3lbljoredhcwv6u

1 reference

https://api.fatcat.wiki/v0/release/6n3nphee4rh3lbljoredhcwv6u

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15103391%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40563800&oldid=1837126999"